p-Cymyl-phosphin-(2) | 100211-98-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: p-Cymyl-phosphin-(2)
• 英文别名: p-Cymyl-phosphin-(3)；(2-Methyl-5-propan-2-ylphenyl)phosphane
• CAS: 100211-98-1
• 化学式: C₁₀H₁₅P
• 分子量: 166.203
• InChiKey: RAQPCJBYASQEGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  4-Cymyl-phosphin-dichlorid-(2) 在 lithium aluminium tetrahydride 作用下， 生成 p-Cymyl-phosphin-(2)
  参考文献：
  名称：

  Strubell,W., Journal fur praktische Chemie (Leipzig 1954), 1962, vol. 18, p. 113 - 116

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：NUVATION BIO INC

  公开号：WO2021030623A1

  公开（公告）日：2021-02-18

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供CDK4或CDK6或其他CDK抑制剂作为杂环化合物。这些化合物可能作为治疗药物用于治疗疾病，并且在肿瘤学中可能有特定用途。
• Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
  申请人：Pfizer Inc.

  公开号：US10227346B2

  公开（公告）日：2019-03-12

  The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

  本发明提供甲基和三氟甲基取代的吡咯并吡啶、其药物组合物、调节受试者体内 RORγ 活性和/或减少 IL-17 量的方法，以及使用此类吡咯并吡啶及其药物组合物治疗各种疾病的方法。
• Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10246483B2

  公开（公告）日：2019-04-02

  The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

  本发明提供了式 I 的化合物： 包含这些化合物的药物组合物，以及使用这些化合物治疗或预防由 FXR 和/或 TGR5 介导的疾病或紊乱的方法。
• Substituted Pyrrolidine Compounds
  申请人：EPIZYME, INC.

  公开号：US20170253601A1

  公开（公告）日：2017-09-07

  The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
  申请人：Pfizer Inc.

  公开号：US20180170928A1

  公开（公告）日：2018-06-21

  The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.